Early Clinical Outcomes of a Novel Antibiotic-Coated, Non-Crosslinked Porcine Acellular Dermal Graft after Complex Abdominal Wall Reconstruction
- 1 October 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (4) , 581-586
Abstract
Non-crosslinked porcine acellular dermal grafts (NCPADG) are currently the mainstay biomaterial for abdominal wall reconstruction (AWR) in complex hernia patients. We report early clinical outcomes using a novel rifampin/minocycline-coated NCPADG for AWR. A multi-institutional retrospective review was performed of patients who underwent ventral hernia repair using XenMatrix AB Surgical Graft (CR Bard, Inc [Davol]). Patient demographics, hernia and procedure characteristics, and surgical site occurrences/postoperative complications were reviewed up to 6 months after AWR. Seventy-four patients underwent AWR using XenMatrix AB Surgical Graft. Open AWR was performed in 52 patients (70.3%), and 22 patients (29.7%) underwent laparoscopic VHR. Median hernia size/area was 66.0 cm(2) (range 9.4 to 294.5 cm(2)). Sixteen patients (21.6%) had previous wound infections, and 16 patients (21.6%) had violation of the gastrointestinal tract during hernia repair. The most common locations of NCPADG placement were within the intraperitoneal (32.4%) and onlay (21.6%) positions, respectively. Median hospital length of stay was 4 days. Within 30 days after AWR, 6 (8.1%) patients were readmitted, postoperative seroma formation developed in 4 (5.4%) patients, 1 patient required percutaneous drainage, and surgical site infections developed in 5 (6.8%) patients. At 6 months follow-up, hernia recurrence had developed in 4 (5.4%) patients. Data suggest that use of a novel rifampin/minocycline-coated NCPADG was associated with a low rate of postoperative surgical site occurrences/postoperative complications during the first 30 days of follow-up in complex AWR patients. In addition, data suggest a low rate of hernia recurrence at 6-month follow-up. Additional study is warranted to determine whether early antimicrobial protection of the device translates into longer-term protection of the repair.Keywords
This publication has 13 references indexed in Scilit:
- The retrospective chart review: important methodological considerationsJournal of Educational Evaluation for Health Professions, 2013
- Biologic Versus Nonbiologic Mesh in Ventral Hernia Repair: A Systematic Review and Meta‐analysisWorld Journal of Surgery, 2013
- Low-density polypropylene meshes coated with resorbable and biocompatible hydrophilic polymers as controlled release agents of antibioticsActa Biomaterialia, 2013
- Biologic grafts for ventral hernia repair: a systematic reviewThe American Journal of Surgery, 2013
- Modified Hernia Grading Scale to Stratify Surgical Site Occurrence after Open Ventral Hernia RepairsJournal of the American College of Surgeons, 2012
- Multilayer, degradable coating as a carrier for the sustained release of antibiotics: Preparation and antimicrobial efficacy in vitroJournal of Controlled Release, 2012
- New antibiotic-eluting mesh used for soft tissue reinforcementActa Biomaterialia, 2011
- Bacterial clearance of biologic grafts used in hernia repair: an experimental studySurgical Endoscopy, 2011
- Antibiotic-Releasing Mesh Coating to Reduce Prosthetic Sepsis: An In Vivo StudyJournal of Surgical Research, 2010
- Human Acellular Dermal Matrix for Repair of Abdominal Wall Defects: Review of Clinical Experience and Experimental DataJournal of Long-Term Effects of Medical Implants, 2005